Brilliant Violet 510™ anti-mouse CD8a Antibody

Catalog# / Size	100751 / 125 µL 100752 / 50 µg
Clone	53-6.7
Regulatory Status	RUO
Other Names	T8, Lyt2, Ly-2
Isotype	Rat IgG2a, κ
Description	CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details

Verified Reactivity	Mouse
Antibody Type	Monoclonal
Host Species	Rat
Immunogen	Mouse thymus or spleen
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation	The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 510™ under optimal conditions.
Concentration	µg sizes: 0.2 mg/mL µL sizes: lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. **Do not freeze.**
Application	FC - Quality tested
Recommended Usage	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. For immunofluorescent staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application. Brilliant Violet 510™ excites at 405 nm and emits at 510 nm. The bandpass filter 510/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. **Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel.** Refer to your instrument manual or manufacturer for support. Brilliant Violet 510™ is a trademark of Sirigen Group Ltd. Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Excitation Laser

Violet Laser (405 nm)

Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes[3]. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of $CD8a^+$ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation[1,3], *in vivo* and *in vitro* cell depletion[2,10,15], inhibition of CD8 T cell proliferation[3], blocking of cytotoxicity[3,4], immunohistochemical staining[5,6] of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)[29,30]. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Application References

(PubMed link indicates BioLegend citation)

1. Ledbetter JA, *et al.* 1979. *Immunol. Rev.* 47:63. (IHC, IP)
2. Hathcock KS. 1991. *Current Protocols in Immunology.* 3.4.1. (Deplete)
3. Takahashi K, *et al.* 1992. *P. Natl. Acad. Sci. USA* 89:5557. (Block, IP)
4. Ledbetter JA, *et al.* 1981. *J. Exp. Med.* 153:1503. (Block)
5. Hata H, *et al.* 2004. *J. Clin. Invest.* 114:582. (IHC)
6. Fan WY, *et al.* 2001. *Exp. Biol. Med.* 226:1045. (IHC)
7. Shih FF, *et al.* 2006. *J. Immunol.* 176:3438. (FC)
8. Kamimura D, *et al.* 2006. *J. Immunol.* 177:306.
9. Bouwer HGA, *et al.* 2006. *P. Natl. Acad. Sci. USA* 103:5102. (FC, Deplete)
10. Kao C, *et al.* 2005. *Int. Immunol.* 17:1607. PubMed
11. Ko SY, *et al.* 2005. *J. Immunol.* 175:3309. (FC) PubMed
12. Rasmussen JW, *et al.* 2006. *Infect. Immun.* 74:6590. PubMed
13. Lee CH, *et al.* 2009. *Clin. Cancer Res.* PubMed
14. Geiben-Lynn R, *et al.* 2008. *Blood* 112:4585. (Deplete) PubMed
15. Kingeter LM, *et al.* 2008. *J. Immunol.* 181:6244. PubMed
16. Guo Y, *et al.* 2008. *Blood* 112:480. PubMed
17. Andrews DM, *et al.* 2008. *J. Virol.* 82:4931. PubMed
18. Britschqui MR, *et al.* 2008. *J. Immunol.* 181:7681. PubMed
19. Kenna TJ, *et al.* 2008. *Blood* 111:2091. PubMed
20. Jordan JM, *et al.* 2008. *Infect. Immun.* 76:3717. PubMed
21. Todd DJ, *et al.* 2009. *J. Exp. Med.* 206:2151. PubMed
22. Bankoti J, *et al.* 2010. *Toxicol. Sci.* 115:422. (FC) PubMed
23. Medyouf H, *et al.* 2010. *Blood* 115:1175. PubMed
24. Riedl P, *et al.* 2009. *J. Immunol.* 183:370. PubMed
25. Apte SH, *et al.* 2010. *J. Immunol.* 185:998. PubMed
26. Bankoti J, *et al.* 2010. *Toxicol. Sci.* 115:422. (FC) PubMed
27. del Rio ML, *et al.* 2011. *Transpl. Int.* 24:501. (FC) PubMed
28. Cui L, *et al.* 2015. *J Control Release.* 206:220. PubMed
29. Radtke AJ, *et al.* 2020. *Proc Natl Acad Sci U S A.* 117:33455-65. (SB) PubMed
30. Radtke AJ, *et al.* 2022. *Nat Protoc.* 17:378-401. (SB) PubMed

Product Citations

1. Saha D *et al.* 2017. Cancer cell. 32(2):253-267 . PubMed
2. Li SX, *et al.* 2019. PLoS Pathog. 15:e1007611. PubMed
3. Luo J, *et al.* 2022. J Nanobiotechnology. 20:228. PubMed
4. Kim S, *et al.* 2020. Immunity. 53(4):759-774.e9. PubMed
5. Zhang LJ, *et al.* 2019. Immunity. 50:121. PubMed
6. Wilfahrt D, *et al.* 2021. Elife. 10:. PubMed
7. Otano I, *et al.* 2021. Nat Commun. 12:7296. PubMed
8. Zhou J, *et al.* 2021. Int J Med Sci. 18:3516. PubMed
9. Lino AC *et al.* 2018. Immunity. 49(1):120-133 . PubMed
10. Wang D, *et al.* 2018. Immunity. 48:659. PubMed
11. Baldwin SL, *et al.* 2021. PLoS One. 16:e0247990. PubMed
12. Stegelmeier AA, *et al.* 2022. Biomedicines. 10:. PubMed
13. Steubing RD, *et al.* 2022. Brain Behav Immun Health. 24:100493. PubMed
14. Wang C, *et al.* 2015. Sci Rep. 5: 14124. PubMed
15. Larsen SE, *et al.* 2021. Sci Rep. 11:9040. PubMed
16. Chen J, *et al.* 2022. J Nanobiotechnology. 20:283. PubMed
17. Rodriguez-Ruiz M, *et al.* 2016. Cancer Res . 76: 5994 - 6005. PubMed
18. Fuster JJ, *et al.* 2020. Cell Rep. 33:108326. PubMed
19. Si Y, *et al.* 2020. Sci Adv. 6:eaba0995. PubMed
20. Matsuoka S, *et al.* 2019. Haematologica. 105:226. PubMed
21. Gajdasik DW, *et al.* 2020. Nat Commun. 2.834027778. PubMed
22. Jenkins RW, *et al.* 2018. Cancer Discov. 8:196. PubMed
23. Müller M, *et al.* 2021. Nat Commun. 12:7036. PubMed
24. Tuttle KD, *et al.* 2020. Cell Rep. 33:108407. PubMed
25. Dikiy S, *et al.* 2021. Immunity. 54(5):931-946.e11. PubMed
26. Flommersfeld S, *et al.* 2021. Immunity. :. PubMed
27. Aegerter H, *et al.* 2020. Nat Immunol. 0.975694444. PubMed
28. Lissner MM, *et al.* 2020. Elife. 9:00. PubMed
29. Hiramoto T, *et al.* 2018. Mol Ther. 26:1255. PubMed
30. Yang L, *et al.* 2021. Cell Death Differ. 28:2616. PubMed
31. Bogie JF, *et al.* 2020. Ther Adv Chronic Dis. 11:2040622320947378. PubMed
32. Koivisto CS, *et al.* 2020. Neoplasia. 1.252777778. PubMed
33. Dietmar Herndler-Brandstetter *et al.* 2018. Immunity. 48(4):716-729 . PubMed

34. Telford W, *et al.* 2017. Cytometry A. 91:314. PubMed
35. Leylek R, *et al.* 2019. Cell Rep. 29:3736. PubMed
36. Yu X, *et al.* 2020. Cancer Cell. 37(6):850-866. PubMed
37. Friedman DJ, *et al.* 2021. Cancer Immunol Res. 9:952. PubMed
38. Knizkova D, *et al.* 2022. Nat Immunol. 23:1644. PubMed
39. Mulas F, *et al.* 2020. Cell Mol Immunol. . PubMed
40. Ringel AE, *et al.* 2020. Cell. 183(7):1848-1866.e26. PubMed
41. Liu CY, *et al.* 2020. Cell Rep. 33:108275. PubMed
42. Jing Y, *et al.* 2020. Sci Adv. 6:eaax9455. PubMed
43. Bradley KC, *et al.* 2019. Cell Rep. 28:245. PubMed
44. Luo J, *et al.* 2022. J Nanobiotechnology. 20:228. PubMed
45. Cosentino K, *et al.* 2022. Mol Cell. 82:933. PubMed
46. Vogel A, *et al.* 2022. STAR Protoc. 3:101653. PubMed
47. Ni J, *et al.* 2020. Immunity. 52(6):1075-1087.e8. PubMed
48. Kyburz A, *et al.* 2019. J Allergy Clin Immunol. 143:1496. PubMed
49. Moore MJ *et al.* 2018. eLife. 7 pii: e33057. PubMed
50. Puigdelloses M, *et al.* 2021. J Immunother Cancer. 9:. PubMed
51. Ma X, *et al.* 2020. Immunity. 53:1315. PubMed
52. van Vloten JP, *et al.* 2019. Mol Ther Methods Clin Dev. 13:154. PubMed
53. Kyburz A, *et al.* 2017. Clin Exp Allergy. 47:1331. PubMed
54. Cosway EJ, *et al.* 2017. J Exp Med. 214:3183. PubMed
55. Ge C, *et al.* 2020. Cell Reports. 29(13):4236-4244.e3.. PubMed
56. Souza SP, *et al.* 2021. PLoS Pathog. 17:e1010081. PubMed
57. Loo CS, *et al.* 2020. Immunity. 53:143. PubMed
58. Zhu D, *et al.* 2017. Stem Cell Res Ther. 0.511805556. PubMed
59. Fowler AM *et al.* 2018. Cell host & microbe. 24(5):743-750 . PubMed
60. Varikuti S, *et al.* 2020. Br J Cancer. 122:1005. PubMed
61. Jiang L, *et al.* 2020. Cell. 183(5):1219-1233.e18. PubMed
62. Soukup K, *et al.* 2017. Sci Rep. 10.1038/s41598-017-12208-7. PubMed
63. Urata S, *et al.* 2018. PLoS Pathog. 14:e1007172. PubMed
64. Mao W, *et al.* 2019. J Immunother Cancer. 0.484027778. PubMed
65. Wang D, *et al.* 2022. EMBO Rep. 23:e53691. PubMed
66. Tsai HI, *et al.* 2021. EMBO Mol Med. 13:e12834. PubMed
67. Mairhofer D, *et al.* 2015. J Invest Dermatol. 135: 2785-93. PubMed
68. Chen Y, *et al.* 2021. Nat Immunol. 22:996. PubMed
69. Kim MY, *et al.* 2022. Nat Commun. 13:3296. PubMed
70. Vogel A, *et al.* 2022. Cell Rep. 38:110420. PubMed
71. Di Pilato M, *et al.* 2021. Cell. 184(17):4512-4530.e22. PubMed
72. Bommareddy PK, *et al.* 2019. J Biol Methods. 6:2. PubMed
73. Schaftenaar FH, *et al.* 2019. Sci Rep. 9:17391. PubMed
74. Sun Y, *et al.* 2020. J Immunol. 205:2649. PubMed
75. Wang R, *et al.* 2022. J Immunother Cancer. 10:. PubMed
76. Tzeng TT, *et al.* 2022. NPJ Vaccines. 7:60. PubMed
77. Teijeira á, *et al.* 2020. Immunity. 52(5):856-871. PubMed
78. Tao Z, *et al.* 2022. Cells. 11:. PubMed
79. McAusland TM, *et al.* 2021. Mol Ther Oncolytics. 20:306. PubMed
80. Wang T, *et al.* 2015. Proc Natl Acad Sci U S A. 112:440. PubMed
81. Wang X, *et al.* 2021. Immunity. 54(6):1123-1136.e8. PubMed
82. Rappe JCF, *et al.* 2021. J Exp Med. 218:. PubMed
83. Du Z, *et al.* 2020. J Allergy Clin Immunol. . PubMed
84. Jiang W, *et al.* 2021. Cell Rep. 37:110112. PubMed
85. Zhang L, *et al.* 2021. Mol Ther. 29:744. PubMed
86. Liu Y, *et al.* 2021. Nat Commun. 12:6831. PubMed

RRID

AB_2561389 (BioLegend Cat. No. 100751)
AB_2563057 (BioLegend Cat. No. 100752)

Antigen Details

Structure	Ig superfamily, CD8α chain, 34 kD
Distribution	Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells
Function	Co-receptor for TCR
Ligand/Receptor	MHC class I molecule
Antigen References	1. Barclay A, *et al.* 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Zamoyska R. 1994. *Immunity* 1:243. 3. Ellmeier W, *et al.* 1999. *Annu. Rev. Immunol.* 17:523.
Gene ID	12525

Related Protocols

Cell Surface Flow Cytometry Staining Protocol

Other Formats

APC anti-mouse CD8a, Biotin anti-mouse CD8a, FITC anti-mouse CD8a, PE anti-mouse CD8a, PE/Cyanine5 anti-mouse CD8a, Purified anti-mouse CD8a, PE/Cyanine7 anti-mouse CD8a, APC/Cyanine7 anti-mouse CD8a, Alexa Fluor® 488 anti-mouse CD8a, Alexa Fluor® 647 anti-mouse CD8a, Pacific Blue™ anti-mouse CD8a, Alexa Fluor® 700 anti-mouse CD8a, PerCP/Cyanine5.5 anti-mouse CD8a, PerCP anti-mouse CD8a, Brilliant Violet 421™ anti-mouse CD8a, Brilliant Violet 570™ anti-mouse CD8a, Brilliant Violet 650™ anti-mouse CD8a, Brilliant Violet 605™ anti-mouse CD8a, Ultra-LEAF™ Purified anti-mouse CD8a, Brilliant Violet 711™ anti-mouse CD8a, Brilliant Violet 785™ anti-mouse CD8a, Brilliant Violet 510™ anti-mouse CD8a, Purified anti-mouse CD8a (Maxpar® Ready), Alexa Fluor® 594 anti-mouse CD8a, PE/Dazzle™ 594 anti-mouse CD8a, APC/Fire™ 750 anti-mouse CD8a, GoInVivo™ Purified anti-mouse CD8a, TotalSeq™-A0002 anti-mouse CD8a, Spark Blue™ 550 anti-mouse CD8a, Spark NIR™ 685 anti-mouse CD8a, TotalSeq™-C0002 anti-mouse CD8a, TotalSeq™-B0002 anti-mouse CD8a, Spark YG™ 570 anti-mouse CD8a, PE/Fire™ 640 anti-mouse CD8a, PE/Fire™ 700 anti-mouse CD8a, Spark Blue™ 574 anti-mouse CD8a Antibody, Spark Violet™ 423 anti-mouse CD8a Antibody, Spark UV™ 387 anti-mouse CD8a

Product Data



C57BL/6 mouse splenocytes were stained with CD3 APC and CD8a (clone 53-6.7) Brilliant Violet 510™.

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587